论文部分内容阅读
奥匹卡朋为一新的外周儿茶酚O-甲基转移酶抑制剂,于2016年6月获欧盟委员会批准,用于联合左旋多巴及多巴脱羧酶抑制剂治疗成人帕金森病和剂末症状波动患者。临床试验表明,奥匹卡朋50 mg·d-1的疗效明显优于安慰剂,而且不劣效于恩他卡朋。奥匹卡朋耐受性好,无严重肝功能损害。本文从药效学、药动学、临床疗效及不良反应等方面对奥匹卡朋进行了介绍。
Oxycarbapene, a new peripheral catechin O-methyltransferase inhibitor, was approved by the European Commission in June 2016 for the combined use of levodopa and dopa decarboxylase inhibitors in the treatment of adult Parkinson’s disease and Patients with end-symptoms fluctuations. Clinical trials have shown that oxpacapene 50 mg · d-1 is significantly better than placebo, and not inferior to entecavir. Ophiophapene is well tolerated and has no serious hepatic impairment. In this paper, the pharmacopoeia, pharmacokinetics, clinical efficacy and adverse reactions and other aspects of the Olympics were introduced.